Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG

Zhou, Y., Huang, Q., Lu, T., Sun, X., Fang, L., Lu, Z., Hu, X., Kermode, A. and Qiu, W. (2017) Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG. Journal of Clinical Neuroscience, 38 . pp. 71-73.

Abstract

There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.

Item Type:	Journal Article
Murdoch Affiliation(s):	Institute for Immunology and Infectious Diseases
Publisher:	Churchill Livingstone
Copyright:	© 2017 Elsevier Ltd.
URI:	http://researchrepository.murdoch.edu.au/id/eprint/35170

Item Control Page